Patents by Inventor Thomas C. Malone

Thomas C. Malone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINASE INHIBITORS
    Publication number: 20130310394
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 21, 2013
    Applicant: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • KINASE INHIBITORS
    Publication number: 20130267497
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 10, 2013
    Inventors: Lon T. Spada, Jane-Gou Shiah, Patrick M. Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • KINASE INHIBITORS
    Publication number: 20130237538
    Abstract: The present invention relates to compounds of formulae I and II wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 12, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Clarence E. Hull, III, Thomas C. Malone
  • METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS
    Publication number: 20130237537
    Abstract: The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 12, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Clarence E. Hull, III, Thomas C. Malone
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 8512738
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Joan-En Chang-Lin, Jane Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 8455535
    Abstract: The present invention provides a compound represented by the formula: wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 8455656
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8409607
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: April 2, 2013
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Jeffery L. Edelman, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8404267
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: March 26, 2013
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Jeffery L. Edelman, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • Kinase inhibitors
    Patent number: 8383825
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: February 26, 2013
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Portable transceiver with vehicle security control and locate features
    Patent number: 8380430
    Abstract: A portable transceiver for locking and locating an automobile, includes a remote keyless entry system for locking the automobile; a locating device determining a location of the transceiver, wherein the remote keyless entry system and the locating device are housed in a pocket sized housing; and a processor deriving directional information from a current location to a waypoint, wherein in response to an activation of the remote keyless entry system, the locating device determines the waypoint corresponding substantially to that of the automobile.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: February 19, 2013
    Assignee: Audiovox Corporation
    Inventors: Thomas C. Malone, James R. Tranchina, John DiCroce, Shane Wilson
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 8367664
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: February 5, 2013
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 8338415
    Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as disclosed herein. The present invention also relates to pharmaceutical compositions comprising said compounds and to methods of using said compounds and compositions for modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: December 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Kinase inhibitors
    Publication number: 20120238558
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 26, 2009
    Publication date: September 20, 2012
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Julie A. Wurster, Xialing Guo, Sougato Boral
  • Kinase Inhibitors
    Publication number: 20120207810
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 16, 2012
    Inventors: Lon T. SPADA, Jane Guo SHIAH, Patrick HUGHES, Thomas C. MALONE, Gerald W. DEVRIES, Jeffrey L. EDELMAN, Julie A. WURSTER
  • Kinase inhibitors
    Patent number: 8143410
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: March 27, 2012
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Kinase Inhibitors
    Publication number: 20110263611
    Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
    Type: Application
    Filed: July 7, 2011
    Publication date: October 27, 2011
    Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
  • Heteroaryl Dihydroindolones as Kinase Inhibitors
    Publication number: 20110257238
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 7977351
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 12, 2011
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone